Difference between revisions of "Pharmacokinetics"
m (→Absorption) |
|||
(20 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
− | {{ | + | {{unfinished}} |
− | + | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
'''Pharmacokinetics is the effect that the body has on drugs.''' | '''Pharmacokinetics is the effect that the body has on drugs.''' | ||
+ | |||
+ | |||
All aspects of pharmacokinetics can be covered by the acronym '''ADME''', which stands for: | All aspects of pharmacokinetics can be covered by the acronym '''ADME''', which stands for: | ||
− | + | '''A'''bsorption | |
− | + | ||
− | + | '''D'''istribution | |
− | + | ||
+ | '''M'''etabolism | ||
+ | |||
+ | '''E'''xcretion | ||
These underpin how a clinician chooses to use a drug and a good knowledge of a drug's pharmacokinetics will help one predict when therapeutic failure may occur and to enable one to safely use unliscensed products or multiple drugs on one patient. It must also be remembered that the the follwing factors also have an effect on a drug's pharmacokinetics: | These underpin how a clinician chooses to use a drug and a good knowledge of a drug's pharmacokinetics will help one predict when therapeutic failure may occur and to enable one to safely use unliscensed products or multiple drugs on one patient. It must also be remembered that the the follwing factors also have an effect on a drug's pharmacokinetics: | ||
Line 22: | Line 20: | ||
* age | * age | ||
* drug formulation | * drug formulation | ||
+ | |||
==Absorption== | ==Absorption== | ||
− | |||
− | The ability of a drug to cross the phospholipid bilayer not only | + | Drugs are most usually small molecules (<1000 molecular weight) and thus can pass through cell membranes through '''passive diffusion''' and '''facilitated transport'''. For further information on these processes please look [[Transport Across Membranes - Physiology|here]]. To cross vascular endothelium drugs usually are able to squeeze through the gaps between the cells. The size of these gaps varies between different locations in the bosy; in the liver the gaps ate large but in the central nervous system these gaps are tight junctions. |
+ | |||
+ | |||
+ | The ability of a drug to cross the phospholipid bilayer not only infuences the rate and extent of its absorption but also the rate and extent of it's distribution, metabolism and elimination. | ||
Below are the main factors affecting absorption: | Below are the main factors affecting absorption: | ||
+ | |||
===Properties of the Drug=== | ===Properties of the Drug=== | ||
− | * Lipid solubility - the more lipid soluble a drug the | + | |
− | * Chemical nature - ie. Is it basic or acidic? Is it | + | * Lipid solubility - the more lipid soluble a drug the easier it is absorbed across the bilayer |
− | * Molecular weight | + | * Chemical nature - ie. Is it basic or acidic? Is it ionised or not? |
− | * Stability in the | + | * Molecular weight |
+ | * Stability in the gastro-intestinal tract - only applies to orally administered drugs | ||
+ | |||
===Physiological Variables=== | ===Physiological Variables=== | ||
+ | |||
* '''pH at site of absorption''' | * '''pH at site of absorption''' | ||
− | Many drugs are either a '''weak base''' or a '''weak acid''' and so will exist in both an | + | Many drugs are either a '''weak base''' or a '''weak acid''' and so will exist in both an unionised and ionised form in the same solution. The ratio of the two forms is dependent upon the pH of the location of the drug. It must be remembered that ionised molecules don't pass easily through lipid membranes. Unionised molecules will diffuse easily as long as they are lipid soluble. |
− | The | + | The ionisation reaction of a weak acid is |
AH =<sup>'''Ka'''</sup> A<sup>-</sup> + H<sup>+</sup> | AH =<sup>'''Ka'''</sup> A<sup>-</sup> + H<sup>+</sup> | ||
Line 49: | Line 54: | ||
pK<sub>a</sub> = pH + log<sub>10</sub> ([AH]/[A<sup>-</sup>]) | pK<sub>a</sub> = pH + log<sub>10</sub> ([AH]/[A<sup>-</sup>]) | ||
− | The | + | The ionisation reaction of a weak base is |
BH<sup>+</sup> =<sup>'''Ka'''</sup> B + H<sup>+</sup> | BH<sup>+</sup> =<sup>'''Ka'''</sup> B + H<sup>+</sup> | ||
Line 57: | Line 62: | ||
pK<sub>a</sub> = pH + log<sub>10</sub> ([BH<sup>+</sup>]/[B]) | pK<sub>a</sub> = pH + log<sub>10</sub> ([BH<sup>+</sup>]/[B]) | ||
− | |||
− | Due to the above | + | The dissociaton constant allows one to measure the strength of an acid or base and to determine the charge on a molecule in any givem pH. |
+ | |||
+ | Thus the extent of ionisation of a drug and so it's extent of absorbtion, depneds upon its '''pK<sub>a</sub>''' and the pH within the body compartment. | ||
+ | |||
+ | Due to the above drugs can become '''ion trapped''' in certain body compartments. If it is assumed that the ionised fraction is unable to cross cell membranes and the unionised fraction is; then a weak acid will become greatly concentrated in an environment with a high pH. This is because it will donate it's spare protons to the basic elements in the high pH environment and then will be unable to cross out of the environment as the drug is now ionised; it has been '''trapped'''. | ||
'''Insert Diagram Here''' | '''Insert Diagram Here''' | ||
− | '''In summary | + | '''In summary a weakly acidic drug will become ion trapped in an environment with a high pH and a weakly basic drug will become ion trapped in an environment with a low pH.''' |
+ | |||
* '''The Area of the absorbing surface''' | * '''The Area of the absorbing surface''' | ||
The larger the surface area for absorption the greater the absorption. | The larger the surface area for absorption the greater the absorption. | ||
+ | |||
* '''Local Blood Flow''' | * '''Local Blood Flow''' | ||
The greater the blood flow the greater the rate of absorption. | The greater the blood flow the greater the rate of absorption. | ||
+ | |||
===Route of Adminstration=== | ===Route of Adminstration=== | ||
+ | |||
Drugs can be given via a variety of routes. A choice of a specific route is determined by the following factors: | Drugs can be given via a variety of routes. A choice of a specific route is determined by the following factors: | ||
* the properties of the drug | * the properties of the drug | ||
Line 77: | Line 89: | ||
'''Intravenous injections''' have the highest peak plasma concentrations after administration. | '''Intravenous injections''' have the highest peak plasma concentrations after administration. | ||
+ | |||
===Formulation=== | ===Formulation=== | ||
+ | |||
For a drug to be absorbed it must be in an aqueous solution. Thus the rate of absorbtion of an injectable formulation is influenced by it's aqueous solubility. As the solubility decreases the rate of absorbtion and thus its plasma concentration is lower. | For a drug to be absorbed it must be in an aqueous solution. Thus the rate of absorbtion of an injectable formulation is influenced by it's aqueous solubility. As the solubility decreases the rate of absorbtion and thus its plasma concentration is lower. | ||
Line 85: | Line 99: | ||
'''Cmax''' = The maximum concentration that the drug will reach in that formulation in the body system. | '''Cmax''' = The maximum concentration that the drug will reach in that formulation in the body system. | ||
− | '''Tmax''' = The time it takes to | + | '''Tmax''' = The time it takes to recah the Cmax. |
+ | |||
====Oral Formulations==== | ====Oral Formulations==== | ||
+ | |||
Usually 75% of a drug is absorbed in 2-3 hours when given orally. The following factors affect their absorption: | Usually 75% of a drug is absorbed in 2-3 hours when given orally. The following factors affect their absorption: | ||
Line 98: | Line 114: | ||
* Presence of food - it can delay drug absorption without changing the amount absorbed, it can delay the absorption and decrease the amount absorbed or it can increase the rate and amount absorbed. | * Presence of food - it can delay drug absorption without changing the amount absorbed, it can delay the absorption and decrease the amount absorbed or it can increase the rate and amount absorbed. | ||
* First Pass Metabolism - a drug can be extensively metabolised before reaching the systemic circulation. This can occur in the gastro-intestinal tract wall, in the portal circulation and in the liver. | * First Pass Metabolism - a drug can be extensively metabolised before reaching the systemic circulation. This can occur in the gastro-intestinal tract wall, in the portal circulation and in the liver. | ||
+ | |||
====Bioavailability==== | ====Bioavailability==== | ||
+ | |||
This is the fraction of the administered drug that actually reaches the systemic circulation in its active form. It is expressed as a percentage of the total amount administered and is calculated using plasma drug concentrations. | This is the fraction of the administered drug that actually reaches the systemic circulation in its active form. It is expressed as a percentage of the total amount administered and is calculated using plasma drug concentrations. | ||
To calculate bioavailability a curve of time against plasma concentration of a drug must be drawn in both it's intravenous form and then whichever form is underinvestigation, say intramuscular. Then use the following equation to calcute it: | To calculate bioavailability a curve of time against plasma concentration of a drug must be drawn in both it's intravenous form and then whichever form is underinvestigation, say intramuscular. Then use the following equation to calcute it: | ||
− | Bioavailability = (Area Under Curve IM/Area under curve IV) x 100% | + | Bioavailability = (Area Under Curve IM/Area under curve IV) x 100% |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− |
Revision as of 14:20, 21 October 2008
This article is still under construction. |
Pharmacokinetics is the effect that the body has on drugs.
All aspects of pharmacokinetics can be covered by the acronym ADME, which stands for:
Absorption
Distribution
Metabolism
Excretion
These underpin how a clinician chooses to use a drug and a good knowledge of a drug's pharmacokinetics will help one predict when therapeutic failure may occur and to enable one to safely use unliscensed products or multiple drugs on one patient. It must also be remembered that the the follwing factors also have an effect on a drug's pharmacokinetics:
- renal, hepatic and gastrointestinal disease
- multiple drug therapy
- species treated
- age
- drug formulation
Absorption
Drugs are most usually small molecules (<1000 molecular weight) and thus can pass through cell membranes through passive diffusion and facilitated transport. For further information on these processes please look here. To cross vascular endothelium drugs usually are able to squeeze through the gaps between the cells. The size of these gaps varies between different locations in the bosy; in the liver the gaps ate large but in the central nervous system these gaps are tight junctions.
The ability of a drug to cross the phospholipid bilayer not only infuences the rate and extent of its absorption but also the rate and extent of it's distribution, metabolism and elimination.
Below are the main factors affecting absorption:
Properties of the Drug
- Lipid solubility - the more lipid soluble a drug the easier it is absorbed across the bilayer
- Chemical nature - ie. Is it basic or acidic? Is it ionised or not?
- Molecular weight
- Stability in the gastro-intestinal tract - only applies to orally administered drugs
Physiological Variables
- pH at site of absorption
Many drugs are either a weak base or a weak acid and so will exist in both an unionised and ionised form in the same solution. The ratio of the two forms is dependent upon the pH of the location of the drug. It must be remembered that ionised molecules don't pass easily through lipid membranes. Unionised molecules will diffuse easily as long as they are lipid soluble.
The ionisation reaction of a weak acid is
AH =Ka A- + H+
and its dissociation constant pKa is given by the Henderson-Hasselbach equation:
pKa = pH + log10 ([AH]/[A-])
The ionisation reaction of a weak base is
BH+ =Ka B + H+
and its dissociation constant pKa is given by the Henderson-Hasselbach equation:
pKa = pH + log10 ([BH+]/[B])
The dissociaton constant allows one to measure the strength of an acid or base and to determine the charge on a molecule in any givem pH.
Thus the extent of ionisation of a drug and so it's extent of absorbtion, depneds upon its pKa and the pH within the body compartment.
Due to the above drugs can become ion trapped in certain body compartments. If it is assumed that the ionised fraction is unable to cross cell membranes and the unionised fraction is; then a weak acid will become greatly concentrated in an environment with a high pH. This is because it will donate it's spare protons to the basic elements in the high pH environment and then will be unable to cross out of the environment as the drug is now ionised; it has been trapped.
Insert Diagram Here
In summary a weakly acidic drug will become ion trapped in an environment with a high pH and a weakly basic drug will become ion trapped in an environment with a low pH.
- The Area of the absorbing surface
The larger the surface area for absorption the greater the absorption.
- Local Blood Flow
The greater the blood flow the greater the rate of absorption.
Route of Adminstration
Drugs can be given via a variety of routes. A choice of a specific route is determined by the following factors:
- the properties of the drug
- the therapeutic objective (eg speed on onset, length of duration)
- administration or restriction to a local site
Some of the route options are: oral, rectal, intravenous, intramuscular, sub-cutaneous, intra-articular, inhalation, transdermal patches, topical (eye, ear and nose drops), intramammary, intravaginal, epidural and sub-conjunctival.
Intravenous injections have the highest peak plasma concentrations after administration.
Formulation
For a drug to be absorbed it must be in an aqueous solution. Thus the rate of absorbtion of an injectable formulation is influenced by it's aqueous solubility. As the solubility decreases the rate of absorbtion and thus its plasma concentration is lower.
When considering formulations of drugs it is important to look at their Cmax and Tmax values.
Cmax = The maximum concentration that the drug will reach in that formulation in the body system.
Tmax = The time it takes to recah the Cmax.
Oral Formulations
Usually 75% of a drug is absorbed in 2-3 hours when given orally. The following factors affect their absorption:
- Tablet structure and size - this can be altered to change Tmax and Cmax
- Stomach enzymes - can breakdown the drug
- Stomach acidity - some drugs are unstable in such an acidic environment, others will be ion trapped
- Gastric motility - with increased motility there is less time for the drug to absorbed
- Damage to the epithelial barrier - either due to drugs or disease will result in reduced absorbtion
- Stability of the drug in the gastrointestinal tract
- Presence of food - it can delay drug absorption without changing the amount absorbed, it can delay the absorption and decrease the amount absorbed or it can increase the rate and amount absorbed.
- First Pass Metabolism - a drug can be extensively metabolised before reaching the systemic circulation. This can occur in the gastro-intestinal tract wall, in the portal circulation and in the liver.
Bioavailability
This is the fraction of the administered drug that actually reaches the systemic circulation in its active form. It is expressed as a percentage of the total amount administered and is calculated using plasma drug concentrations.
To calculate bioavailability a curve of time against plasma concentration of a drug must be drawn in both it's intravenous form and then whichever form is underinvestigation, say intramuscular. Then use the following equation to calcute it:
Bioavailability = (Area Under Curve IM/Area under curve IV) x 100%